Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.19101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hyperbilirubinemia in Neonates with Blood Group Incompatibilities - a bane or a boon for the management.
Transfus Clin Biol
January 2025
Department of Community Medicine, SCB Medical College & Hospital, Cuttack, Odisha, India. Electronic address:
Objectives: Neonatal hyperbilirubinemia, or newborn jaundice, is a common condition caused by high bilirubin levels. Blood group incompatibility between mother and baby is a major cause. This study examined the link between different blood group incompatibilities and their management in newborns with jaundice.
View Article and Find Full Text PDFABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate.
Transfusion
January 2025
Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Article Synopsis
- This study investigates the balance between avoiding platelet wastage and ensuring transfusion efficacy, focusing on the effects of platelet compatibility and product modification on reaction rates.
- A review of over 21,000 platelet transfusions revealed a 1.33% reaction rate, with major incompatibility and irradiated products associated with increased odds of adverse reactions.
- The findings suggest that both platelet compatibility and product modification independently impact transfusion reactions, informing future policies for selecting platelet products for patients.
Major ABO Incompatibility in Non-Myeloablative Hematopoietic Stem Cell Transplant for Sickle Cell Disease-Not an Insurmountable Obstacle.
Pediatr Blood Cancer
January 2025
Blood and Marrow Transplant/Cellular Therapy Program, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
With advances in conditioning strategies and graft-versus-host disease (GvHD) prevention, hematopoietic stem cell transplantation (HSCT) is a safe, curative treatment option for pediatric patients with sickle cell disease (SCD). However, donor options have been limited in non-myeloablative matched sibling donor (MSD) setting by excluding recipients with major ABO blood group incompatible donors due to concern of the risk of significant complications such as pure red cell aplasia (PRCA). We present three cases of successful HSCT with major ABO incompatibility with their donors, and discuss strategies to safely expand the donor pool to include these donors.
View Article and Find Full Text PDFIn silico design and computational screening of berberine derivatives for potential antidiabetic activity through allosteric activation of the AMPK pathway.
In Silico Pharmacol
January 2025
Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786004 India.
Unlabelled: Globally, there is an increase in the prevalence of metabolic illnesses, including diabetes mellitus. However, current therapies for diabetes and other metabolic illnesses are not well understood. Pharmacological treatment of type 2 diabetes is challenging, moreover, the majority of antidiabetic medications are incompatible with individuals who have cardiac disease, renal illness, or liver damage.
View Article and Find Full Text PDFThe ambiguous role of partially protected marine protected areas in Australia: Results from a systematic literature review.
PLoS One
January 2025
Institute for Marine and Antarctic Studies, The University of Tasmania, Australia.
Marine protected areas (MPAs) are an important tool in helping to protect biodiversity in the oceans. Recent ratification of the Kunming-Montreal Global Biodiversity Framework (GBF) has ensured that globally we are committed to effectively protecting 30% of the world's oceans by 2030, in MPAs. In Australia there is considerable interest in the potential benefits that partially protected areas (PPAs) may provide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!